Product image of Letrozol Cinfa (Letrozole) supplied by GNH India

Letrozol Cinfa

Active Ingredient:
Letrozole
Origin:
EU

Letrozol Cinfa (Letrozole)

Letrozole, the active ingredient in Letrozol Cinfa, is an aromatase inhibitor presented as an oral tablet for oral use. It acts by selective non‑steroidal inhibition of the aromatase enzyme, decreasing peripheral estrogen synthesis, and is employed in the endocrine therapy of estrogen receptor‑positive breast cancer in postmenopausal women.

GNH India supplies Letrozol Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements across EU and global markets.

Manufacturer / TM Owner

Laboratorios Cinfa S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Letrozol Cinfa, an aromatase inhibitor, is used in the management of estrogen‑driven breast cancer.

  • Early‑stage estrogen receptor‑positive breast cancer (adjuvant): reduces recurrence risk.
  • Metastatic estrogen receptor‑positive breast cancer (first‑line): delays disease progression.
  • Hormone‑responsive breast cancer in postmenopausal women: provides endocrine control.

How It Works

  • Letrozole selectively binds to the aromatase enzyme, a cytochrome P450 isoform responsible for converting androstenedione and testosterone to estrone and estradiol. By non‑steroidally inhibiting this enzyme, it markedly lowers peripheral estrogen production, thereby depriving estrogen‑dependent tumor cells of a growth stimulus.

Side Effects

Letrozol Cinfa may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Hot flashes: sudden feeling of warmth and sweating.
  • Joint and muscle pain: arthralgia or myalgia without clear injury.
  • Fatigue: persistent tiredness affecting daily activities.
  • Nausea: mild to moderate upset stomach.
  • Headache: tension‑type or migraine‑like pain.
  • Dizziness: light‑headed sensation, especially when standing.

Serious or Rare Side Effects

  • Severe liver injury: jaundice, elevated transaminases.
  • Osteoporotic fractures: increased risk of bone breakage.
  • Pulmonary embolism or deep‑vein thrombosis: sudden chest pain or leg swelling.
  • Severe allergic reaction: rash, swelling, difficulty breathing.
  • Hypercholesterolemia: significant rise in blood cholesterol levels.
  • Cardiovascular events: hypertension or cardiac ischemia.

Precautions & Warnings

Before initiating Letrozol Cinfa, clinicians should consider several safety measures.

  • Monitor bone mineral density: risk of osteoporosis and fractures.
  • Assess liver function: potential hepatotoxicity requires periodic testing.
  • Evaluate cardiovascular risk: lipid profile changes may occur.
  • Contraindicated in pregnancy: teratogenic potential.
  • Ineffective in premenopausal women: low estrogen levels limit benefit.
  • Store at room temperature: keep below 25°C, protect from moisture and direct sunlight.

Avoid Interactions

Letrozol Cinfa can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

  • Concomitant estrogen therapy: antagonizes letrozole’s aromatase inhibition.
  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce plasma concentrations.
  • Tamoxifen: opposing mechanisms can diminish therapeutic effect.

Moderate Interactions (Monitor Closely)

  • CYP2C19 inhibitors (e.g., fluconazole): may increase letrozole exposure.
  • Warfarin: letrozole can potentiate anticoagulant effect, requiring INR monitoring.
  • Statins: possible increased risk of myopathy when combined.

Frequently Asked Questions

Letrozol Cinfa is used as endocrine therapy for estrogen receptor‑positive breast cancer in postmenopausal women. It is indicated for both early‑stage (adjuvant) and metastatic disease to reduce tumor growth by lowering estrogen levels.

Letrozole works by selectively and non‑steroidally inhibiting the aromatase enzyme, which converts androgens into estrogens. By blocking this conversion, peripheral estrogen production falls dramatically, depriving hormone‑sensitive cancer cells of the estrogen needed for proliferation.

The dosage of Letrozol Cinfa is determined by the prescribing physician based on the patient’s clinical condition, treatment setting, and renal or hepatic function. The prescriber sets the exact amount and schedule, which is typically a once‑daily oral tablet.

Letrozol Cinfa is contraindicated in pregnancy because it can cause fetal harm by disrupting estrogen synthesis. It is also not recommended during breastfeeding, as it may pass into milk and affect the infant’s hormonal balance.

To order Letrozol Cinfa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrozol Cinfa belongs to the same class as anastrozole and exemestane. Compared with anastrozole, letrozole generally provides a slightly stronger suppression of estrogen levels, which may translate into marginally higher efficacy in some settings, while sharing a similar safety profile.

Letrozol Cinfa tablets should be stored at room temperature, below 25 °C, in their original container to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

Letrozol Cinfa is taken orally, usually as a single tablet swallowed whole with water. It can be taken with or without food, but patients should follow the prescriber’s instructions regarding timing and any dietary considerations.

Serious risks include severe liver injury, osteoporotic fractures, pulmonary embolism or deep‑vein thrombosis, and allergic reactions such as anaphylaxis. Patients should be monitored for signs of liver dysfunction, bone loss, and thromboembolic events during therapy.

Letrozol Cinfa should not be used by pregnant or breastfeeding women, premenopausal patients, or individuals with known hypersensitivity to letrozole or any component of the formulation. It is also contraindicated in patients with severe liver impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT